Photodiagnosis and Photodynamic Therapy
Volume 3, Issue 2 , Pages 93-95, June 2006

Endoscopic photodynamic therapy (PDT) for oesophageal cancer

  • Keyvan Moghissi, MD, FRCS (ED & Eng)

      Affiliations

    • Corresponding Author InformationTel.: +44 1724 290456; fax: +44 1724 290456.

The Yorkshire Laser Centre, Goole & District Hospital, Woodland Avenue, Goole, East Yorkshire DN14 6RX, UK

published online 24 April 2006.

Summary 

Endoscopic photodynamic therapy (PDT) is undertaken only when tumour is visible endoscopically with malignancy biopsy confirmed. Patients will be either Group A: inoperable cases with locally advanced cancer when the aim is palliation of dysphagia, or Group E: patients with early stage I–II disease who are unsuitable for surgery or decline operation, when the intent is curative.

Following assessment for suitability for PDT and counselling, Photofrin 2mg/(kgbw) is administered 24–72h before endoscopic illumination using a Diode 630nm laser. Illumination may be either interstitial or intraluminal at a dose of 100–200J/cm.

Keywords: PDT method, Oesophageal cancer

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1572-1000(06)00054-8

doi:10.1016/j.pdpdt.2006.03.005

Photodiagnosis and Photodynamic Therapy
Volume 3, Issue 2 , Pages 93-95, June 2006

Article Tools

* Image Usage & Resolution